Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Dec 2024 value amounting to $2.5 million.

  • Zhengye Biotechnology Holding's Cash & Equivalents was N/A to $6.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2024, which is 19.51% up from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Cash & Equivalents of $2.5 million as of FY2024, which was up 19.51% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Zhengye Biotechnology Holding's Cash & Equivalents peaked at $2.5 million during FY2024, and registered a low of $1.5 million during FY2022.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Cash & Equivalents value was $2.1 million (recorded in 2023), while the average stood at $2.0 million.
  • Data for Zhengye Biotechnology Holding's Cash & Equivalents shows a peak YoY surged of 46.94% (in 2023) over the last 5 years.
  • Zhengye Biotechnology Holding's Cash & Equivalents (Yearly) stood at $1.5 million in 2022, then surged by 46.94% to $2.1 million in 2023, then increased by 19.51% to $2.5 million in 2024.